Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.69 Million EUR | 7.24% |
| 2022 | 23.96 Million EUR | 8.36% |
| 2021 | 22.11 Million EUR | -52.22% |
| 2020 | 46.28 Million EUR | 20.95% |
| 2019 | 38.26 Million EUR | 92.99% |
| 2018 | 19.82 Million EUR | 64.22% |
| 2017 | 12.07 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 28.5 Million EUR | 0.0% |
| 2024 Q1 | 28.5 Million EUR | 10.93% |
| 2023 Q4 | 25.69 Million EUR | 0.0% |
| 2023 Q1 | 24.75 Million EUR | 3.32% |
| 2023 FY | 25.69 Million EUR | 7.24% |
| 2023 Q3 | 25.69 Million EUR | 3.8% |
| 2023 Q2 | 24.75 Million EUR | 0.0% |
| 2022 Q3 | 23.96 Million EUR | 1.54% |
| 2022 Q2 | 23.59 Million EUR | 0.0% |
| 2022 Q4 | 23.96 Million EUR | 0.0% |
| 2022 Q1 | 23.59 Million EUR | 6.72% |
| 2022 FY | 23.96 Million EUR | 8.36% |
| 2021 Q4 | 22.11 Million EUR | 0.0% |
| 2021 FY | 22.11 Million EUR | -52.22% |
| 2021 Q3 | 22.11 Million EUR | -71.12% |
| 2021 Q2 | 76.57 Million EUR | 0.0% |
| 2021 Q1 | 76.57 Million EUR | 65.44% |
| 2020 Q4 | 46.28 Million EUR | 0.0% |
| 2020 Q3 | 46.28 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 46.28 Million EUR | 20.95% |
| 2019 FY | 38.26 Million EUR | 92.99% |
| 2018 FY | 19.82 Million EUR | 64.22% |
| 2017 FY | 12.07 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -271.788% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 80.391% |
| Adocia SA | 31.87 Million EUR | 19.366% |
| Aelis Farma SA | 13.08 Million EUR | -96.468% |
| Biophytis S.A. | 15.84 Million EUR | -62.143% |
| Advicenne S.A. | 24.37 Million EUR | -5.419% |
| genOway Société anonyme | 14.45 Million EUR | -77.724% |
| IntegraGen SA | 5.97 Million EUR | -329.747% |
| Medesis Pharma S.A. | 6.42 Million EUR | -299.895% |
| Neovacs S.A. | 3.71 Million EUR | -592.272% |
| NFL Biosciences SA | 3.62 Million EUR | -609.756% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -278.895% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -676.35% |
| Sensorion SA | 13.22 Million EUR | -94.28% |
| Theranexus Société Anonyme | 5.01 Million EUR | -412.301% |
| TME Pharma N.V. | 2.78 Million EUR | -822.729% |
| Valbiotis SA | 13.7 Million EUR | -87.467% |
| TheraVet SA | 1.48 Million EUR | -1630.513% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -25.552% |
| argenx SE | 402.79 Million EUR | 93.62% |
| BioSenic S.A. | 32.26 Million EUR | 20.351% |
| Celyad Oncology SA | 9.97 Million EUR | -157.547% |
| DBV Technologies S.A. | 38.74 Million USD | 33.675% |
| Galapagos NV | 1.56 Billion EUR | 98.355% |
| Genfit S.A. | 105.92 Million EUR | 75.739% |
| GeNeuro SA | 20.13 Million EUR | -27.597% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -198.398% |
| Innate Pharma S.A. | 132.29 Million EUR | 80.575% |
| Inventiva S.A. | 101.59 Million EUR | 74.705% |
| MaaT Pharma SA | 22.46 Million EUR | -14.391% |
| MedinCell S.A. | 77.77 Million EUR | 66.956% |
| Nanobiotix S.A. | 95.74 Million EUR | 73.159% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -2.279% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 56.502% |
| Oxurion NV | 19.73 Million EUR | -30.209% |
| Pharming Group N.V. | 228.28 Million EUR | 88.743% |
| Poxel S.A. | 53.9 Million EUR | 52.324% |
| GenSight Biologics S.A. | 34.72 Million EUR | 26.0% |
| Transgene SA | 26.51 Million EUR | 3.089% |
| Financière de Tubize SA | 123.65 Million EUR | 79.217% |
| UCB SA | 6.56 Billion EUR | 99.609% |
| Valneva SE | 341.14 Million EUR | 92.467% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -465.164% |